Completed Preclinical (in vivo) 2023

    Synthetic ERR alpha/beta/gamma agonist induces an ERR-alpha-dependent acute aerobic exercise response and enhances exercise capacity

    Billon C, Sitaula S, Banerjee S, et al.

    ACS Chemical Biology

    DOI: 10.1021/acschembio.2c00720

    Summary

    First characterization of SLU-PP-332 as a pan-ERR agonist with highest potency for ERR-alpha. Administration to mice increased type IIa oxidative skeletal muscle fibers, enhanced exercise endurance, and activated an acute aerobic exercise genetic program — establishing it as a pharmacological exercise mimetic.

    Key Findings

    • SLU-PP-332 is a first-in-class pan-ERR agonist targeting all three ERR subtypes
    • Increased type IIa oxidative muscle fibers and enhanced exercise endurance in mice
    • Activated an ERR-alpha-dependent acute aerobic exercise transcriptional program

    Access Full Text

    Read the complete published study from the original source.

    View on Publisher Site

    Related Monographs

    Related Studies

    View all →
    Completed 2024

    Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function

    Xu W, Billon C, Li H, et al.

    Circulation

    Showed that SLU-PP-332 and its successor SLU-PP-915 significantly improved cardiac ejection fraction, reduced fibrosis, and increased survival in pressure overload-induced heart failure. The ERR-gamma-mediated cardioprotection occurs through enhanced fatty acid metabolism and mitochondrial oxidative capacity.

    • SLU-PP-332 improved ejection fraction and increased survival in heart failure model
    • Normalized fatty acid and mitochondrial metabolic profiles in failing hearts

    DOI: 10.1161/CIRCULATIONAHA.123.066542

    Completed 2024

    A synthetic ERR agonist alleviates metabolic syndrome

    Billon C, Schoepke E, Avdagic A, et al.

    Journal of Pharmacology and Experimental Therapeutics

    Demonstrated that SLU-PP-332 mimics exercise-induced metabolic benefits in obese mice, including increased energy expenditure, enhanced fatty acid oxidation, decreased fat mass accumulation, and improved insulin sensitivity. Establishes ERR agonism as a viable approach to treat metabolic syndrome.

    • SLU-PP-332 increased energy expenditure and fatty acid oxidation in diet-induced obese mice
    • Significantly decreased fat mass accumulation without changes in food intake

    DOI: 10.1124/jpet.123.001782